Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Fig 3
ARQ 092 inhibits AKT signaling in AN3CA mouse xenografts, In Vivo.
(A) Tumor samples were assessed by IHC for p-AKT(S473) and p-PRAS40(T246). Veh: Vehicle. (B) p-AKT(S473) and (T308), and p-PRAS40(T246) were assessed by western blot analysis from tumor tissues from and AN3CA mouse xenograft after treatment with 100 or 200 mg/kg. The percentage remaining of the phosphorylated proteins is shown and the vehicle group was designated as 100%.